DefiniGEN’s iPSC-derived intestinal organoids provide a unique in vitro system to model the human intestine. The organoids display a polarized epithelium and harbor a mixture of cell types normally present in the primary intestinal epithelial barrier in vivo, including goblet cells, Paneth cells, enterocytes, and enteroendocrine cells. The cells can be used for drug absorption, metabolism, induction of transporters, and the modelling of infectious disease.
- Highly standardized cell product containing human intestinal organoids with consistent performance and biologically relevant data
- Wild-type donor genetics and karyotype verified
- Multiple cell types identified in the intestinal organoids including epithelial cells, enterocytes, goblet cells, enteroendocrine cells, and Paneth cells
- Cells display multiple key gut markers OLFM4, CHGA, MUC2, Villin and KRT19
- Cells display CYP450 induced activities
- Organoids can be maintained long-term in culture through passaging
Intestinal cell morphology
Typical intestinal organoid morphology is observed in Def-INTESTINAL organoid product. The organoids initially form spheroid structures which over successive passages develop the crypt architecture characteristic of primary human intestinal organoids.
Key intestinal cell marker analysis
Immunocytochemistry analysis has demonstrated that the Def-INT organoids display a polarized epithelium and are composed of differentiated cell types with distinct morphologies. The organoids contain absorptive enterocytes as well as the major secretory lineage cell types including Paneth cells, goblet cells, and enteroendocrine cells.
Def-INT organoids have been demonstrated to display multiple key gut markers. Gene expression analysis shows key intestinal markers including intestinal stem cells (LGR5, Axin2), enterocytes (Vil1, EPCAM), goblet cells (MUC2, FCGBP), Paneth cells (LYZ, DLL4) and enteroendocrine cells (CHGA, GHRL) have similar expression levels in Def-INT organoids and the primary control relative to GAPDH.
Phase I and Phase II metabolism
A range of Phase I and Phase II enzymes have been identified in Def-INT organoids including CYP450, UGT, GST and CES. CYP3A4 is the highest CYP enzyme expressed in the human intestine and is involved in the metabolism of many drugs. Def-INT organoids display activity of CYP3A4 that can be induced upon incubation with RIF and VD3 at the mRNA and protein level. A range of other relevant isoforms of the CYP450 superfamily are also expressed in the organoids, including CYP3A5, CYP2C9, CYP2C19, CYP2J2 and CYP2D6.
Other key enzymes for drug metabolism and detoxification are also active in Def-INT organoids. The intestinal-specific isoform of Carboxilesterase (CES2) shows activity that can be inhibited by Loperamide. GST activity shown is at comparable levels of that found in S9 intestinal fractions and UGT activity is higher than that found in Caco-2 cells.
Transporter expression and activity
Def-INT organoids display gene expression of the key transporters involved in drug uptake and efflux, including MDR1 (ABCB1), BCRP (ABCG2), MRP2 (ABCC2), PEPT1 (SLC15A1) and OATP2B1 (SLCO2B1). Efflux transporters such as MDR1 and MRP2 can be localized in the apical side of Def-INT organoids. Activity of MDR1 has been shown by the ability of organoids to transport Rhodamine123, a MDR1 specific substrate, into the lumen. This activity can be drastically reduced with the competitive inhibitor Verapamil.